Virax Total Stockholder Equity vs Accounts Payable Analysis
| VRAX Stock | USD 2.01 0.07 3.61% |
Virax Biolabs financial indicator trend analysis is much more than just breaking down Virax Biolabs Group prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Virax Biolabs Group is a good investment. Please check the relationship between Virax Biolabs Total Stockholder Equity and its Accounts Payable accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Virax Biolabs Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
Total Stockholder Equity vs Accounts Payable
Total Stockholder Equity vs Accounts Payable Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Virax Biolabs Group Total Stockholder Equity account and Accounts Payable. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Virax Biolabs' Total Stockholder Equity and Accounts Payable is -0.37. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Virax Biolabs Group, assuming nothing else is changed. The correlation between historical values of Virax Biolabs' Total Stockholder Equity and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of Virax Biolabs Group are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Total Stockholder Equity i.e., Virax Biolabs' Total Stockholder Equity and Accounts Payable go up and down completely randomly.
Correlation Coefficient | -0.37 |
| Relationship Direction | Negative |
| Relationship Strength | Insignificant |
Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Accounts Payable
An accounting item on the balance sheet that represents Virax Biolabs obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Virax Biolabs Group are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Most indicators from Virax Biolabs' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Virax Biolabs Group current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Virax Biolabs Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. At this time, Virax Biolabs' Enterprise Value Over EBITDA is fairly stable compared to the past year. Enterprise Value Multiple is likely to rise to 0.30 in 2024, whereas Selling General Administrative is likely to drop slightly above 2.7 M in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 15.4K | 15.5K | 26.9K | 28.3K | Depreciation And Amortization | 1.7M | 1.0 | 103.1K | 97.9K |
Virax Biolabs fundamental ratios Correlations
Click cells to compare fundamentals
Virax Biolabs Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Virax Stock Analysis
When running Virax Biolabs' price analysis, check to measure Virax Biolabs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virax Biolabs is operating at the current time. Most of Virax Biolabs' value examination focuses on studying past and present price action to predict the probability of Virax Biolabs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virax Biolabs' price. Additionally, you may evaluate how the addition of Virax Biolabs to your portfolios can decrease your overall portfolio volatility.